MASS Petroleum (OTCBB: MASP) $0.05. Reported yesterday a recent acquisition in the Western Canadian Basin valued at approximately $403 million (CAD) which includes existing production and undeveloped lands in the oil rich provinces of Alberta and Saskatchewan, which include the Girouxville area of northwestern Alberta. A brief summary of the transaction between NAL Oil & Gas Trust and Breaker Energy Ltd is provided below. MASS Petroleum is currently focused on acquisitions in this highly prospective and producing area.
Key acquisition benefits: Broadens NAL's opportunity base by adding two new core areas at oil- focused Irricana in central Alberta and the Fireweed natural gas property in northeast British Columbia, which, together, represent 60 per cent to 65 per cent of Breaker's current production. Breaker also has production and attractive opportunities at Girouxville, East Prairie and Provost; -- Provides a significant inventory of low-risk development opportunities which are characterized with significant resources in place; -- Operated production (over 90 per cent) with high working interest; -- Contributes approximately 140,000 net undeveloped acres with existing cash flow, reserves, and a stable production base in place.
What They Do: MASS Petroleum is an oil and gas production company backed by an experienced and dedicated management team. MASS Petroleum is engaged in the acquisition of producing oil and natural gas wells, interests and leases from existing companies, governments, and through the open market.
Cerus Corporation (Nasdaq: CERS) $2.56. Today announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety margins for the trial proposed by Cerus, and recommended that the trial design include more stringent safety margins for comparing INTERCEPT-treated platelets and conventional platelets. In addition, the Committee rendered a positive opinion on a proposed pathway forward in which successful completion of the proposed Phase III trial would be followed by a post-marketing randomized control study and concurrent staged roll-out of the product.
The proposed Phase III clinical trial is designed as a randomized, double-blinded, non-inferiority trial to assess the hemostatic efficacy and safety of routine use of INTERCEPT-treated platelets compared to platelets prepared with conventional processes. The proposed primary efficacy endpoint is number of days of Grade 2 bleeding (World Health Organization scale), and the proposed primary safety endpoint is the incidence of acute lung injury (ALI).
What They Do: Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
The U.S. Renewable Energy Group (US-REG) announced Monday after market close that it has signed a cooperation agreement with A-Power Energy Generation Systems (Nasdaq: APWR) $11.58, under which both sides commit mutually to the development and construction of a new production and assembly plant in the United States that will supply highly advanced wind energy turbines to renewable energy projects throughout North and South America. The state-of-the-art facility is expected to be 320,000 square feet and produce 1,100 megawatts of wind energy turbines annually, enough to power 330,000 homes. Upon completion, the facility is expected to employ approximately 1,000 American workers and will create additional jobs during the construction process. In addition to production and assembly at the new plant, the plan calls for many of the key wind turbine components to be sourced from U.S. manufacturers, further expanding the number of jobs created in the United States.
What They Do: A-Power Energy Generation Systems Ltd. ("A-Power"), through its China-based operating subsidiaries, is the largest provider of distributed power generation systems in China, focusing on energy-efficient and environmentally friendly projects of 25MW to 400MW.
BioCryst Pharmaceuticals (Nasdaq: BCRX) $12.32. Today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by BioCryst. Morgan Stanley will be acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers.
What They Do: BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap and penny stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
SmallCapReview.com feature stock reports are intended to be stock ideas, not recommendations. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SCR web site. SCR has been compensated up to three thousand five hundred dollars by a third party HFS for its services with regards to MASS Petroleum.
